Neutralizing TIGIT with anti-TIGIT antibodies has resulted in the partial recoveries of IFNγ and IL-17 expression by CD4+ T cells, suggesting it is a considerable marker to reactivate the immune system against tumor development [146]. Here, CD4 is linked to neoplasm.